NYSE:MED

Medifast Competitors

$235.38
+2.75 (+1.18 %)
(As of 04/21/2021 02:09 PM ET)
Add
Compare
Today's Range
$232.90
Now: $235.38
$236.85
50-Day Range
$207.37
MA: $235.01
$265.82
52-Week Range
$63.16
Now: $235.38
$279.46
Volume1,016 shs
Average Volume124,842 shs
Market Capitalization$2.77 billion
P/E Ratio29.46
Dividend Yield2.42%
Beta1.52

Competitors

Medifast (NYSE:MED) Vs. KOF, ARMK, ACI, SCI, USFD, and BYND

Should you be buying MED stock or one of its competitors? Companies in the sector of "consumer staples" are considered alternatives and competitors to Medifast, including Coca-Cola FEMSA (KOF), Aramark (ARMK), Albertsons Companies (ACI), Service Co. International (SCI), US Foods (USFD), and Beyond Meat (BYND).

Coca-Cola FEMSA (NYSE:KOF) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Dividends

Coca-Cola FEMSA pays an annual dividend of $2.31 per share and has a dividend yield of 4.7%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Coca-Cola FEMSA pays out 77.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast has raised its dividend for 1 consecutive years. Coca-Cola FEMSA is clearly the better dividend stock, given its higher yield and lower payout ratio.

Valuation & Earnings

This table compares Coca-Cola FEMSA and Medifast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coca-Cola FEMSA$10.11 billion1.02$642 million$2.9916.34
Medifast$713.67 million3.88$77.92 million$5.9639.49

Coca-Cola FEMSA has higher revenue and earnings than Medifast. Coca-Cola FEMSA is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

8.4% of Coca-Cola FEMSA shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 1.0% of Coca-Cola FEMSA shares are held by company insiders. Comparatively, 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Coca-Cola FEMSA and Medifast, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Coca-Cola FEMSA02002.00
Medifast00303.00

Coca-Cola FEMSA currently has a consensus price target of $50.00, suggesting a potential upside of 3.26%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Coca-Cola FEMSA.

Profitability

This table compares Coca-Cola FEMSA and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Coca-Cola FEMSA4.86%8.04%3.74%
Medifast11.27%80.07%42.51%

Volatility and Risk

Coca-Cola FEMSA has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Medifast beats Coca-Cola FEMSA on 13 of the 17 factors compared between the two stocks.

Aramark (NYSE:ARMK) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Dividends

Aramark pays an annual dividend of $0.44 per share and has a dividend yield of 1.1%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Aramark pays out -258.8% of its earnings in the form of a dividend. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Aramark has raised its dividend for 1 consecutive years and Medifast has raised its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Aramark and Medifast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aramark$12.83 billion0.77$-461,530,000.00($0.17)-228.24
Medifast$713.67 million3.88$77.92 million$5.9639.49

Medifast has lower revenue, but higher earnings than Aramark. Aramark is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.5% of Aramark shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 10.3% of Aramark shares are held by company insiders. Comparatively, 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aramark and Medifast, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aramark09502.36
Medifast00303.00

Aramark currently has a consensus price target of $32.3077, suggesting a potential downside of 16.43%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Aramark.

Profitability

This table compares Aramark and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aramark-3.60%-1.48%-0.30%
Medifast11.27%80.07%42.51%

Volatility and Risk

Aramark has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Medifast beats Aramark on 10 of the 16 factors compared between the two stocks.

Albertsons Companies (NYSE:ACI) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares Albertsons Companies and Medifast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albertsons Companies$62.46 billion0.15$466.40 millionN/AN/A
Medifast$713.67 million3.88$77.92 million$5.9639.49

Albertsons Companies has higher revenue and earnings than Medifast.

Insider and Institutional Ownership

40.6% of Albertsons Companies shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dividends

Albertsons Companies pays an annual dividend of $0.40 per share and has a dividend yield of 2.0%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast has raised its dividend for 1 consecutive years. Medifast is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Albertsons Companies and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albertsons Companies1.53%99.45%6.10%
Medifast11.27%80.07%42.51%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Albertsons Companies and Medifast, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albertsons Companies231302.61
Medifast00303.00

Albertsons Companies currently has a consensus price target of $19.75, suggesting a potential downside of 0.20%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Albertsons Companies.

Summary

Medifast beats Albertsons Companies on 9 of the 14 factors compared between the two stocks.

Service Co. International (NYSE:SCI) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Valuation and Earnings

This table compares Service Co. International and Medifast's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Service Co. International$3.23 billion2.72$369.60 million$1.9027.28
Medifast$713.67 million3.88$77.92 million$5.9639.49

Service Co. International has higher revenue and earnings than Medifast. Service Co. International is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

83.4% of Service Co. International shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 4.7% of Service Co. International shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Service Co. International has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Dividends

Service Co. International pays an annual dividend of $0.84 per share and has a dividend yield of 1.6%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Service Co. International pays out 44.2% of its earnings in the form of a dividend. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Service Co. International has raised its dividend for 1 consecutive years and Medifast has raised its dividend for 1 consecutive years.

Profitability

This table compares Service Co. International and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Service Co. International13.62%24.63%3.24%
Medifast11.27%80.07%42.51%

Analyst Ratings

This is a breakdown of recent ratings for Service Co. International and Medifast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Service Co. International00403.00
Medifast00303.00

Service Co. International currently has a consensus price target of $49.25, suggesting a potential downside of 5.01%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's higher possible upside, analysts plainly believe Medifast is more favorable than Service Co. International.

Summary

Medifast beats Service Co. International on 8 of the 15 factors compared between the two stocks.

US Foods (NYSE:USFD) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares US Foods and Medifast's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
US Foods$25.94 billion0.33$385 million$2.3816.28
Medifast$713.67 million3.88$77.92 million$5.9639.49

US Foods has higher revenue and earnings than Medifast. US Foods is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

88.8% of US Foods shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 1.0% of US Foods shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

US Foods has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares US Foods and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
US Foods-0.52%4.39%1.27%
Medifast11.27%80.07%42.51%

Analyst Ratings

This is a breakdown of recent ratings for US Foods and Medifast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
US Foods02802.80
Medifast00303.00

US Foods currently has a consensus price target of $40.10, suggesting a potential upside of 3.38%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than US Foods.

Summary

Medifast beats US Foods on 9 of the 14 factors compared between the two stocks.

Beyond Meat (NASDAQ:BYND) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Beyond Meat and Medifast's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beyond Meat$297.90 million27.94$-12,440,000.00($0.04)-3,306.25
Medifast$713.67 million3.88$77.92 million$5.9639.49

Medifast has higher revenue and earnings than Beyond Meat. Beyond Meat is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

42.1% of Beyond Meat shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 11.0% of Beyond Meat shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Beyond Meat has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Beyond Meat and Medifast's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beyond Meat-6.97%-4.49%-3.56%
Medifast11.27%80.07%42.51%

Analyst Ratings

This is a breakdown of recent ratings for Beyond Meat and Medifast, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beyond Meat88301.74
Medifast00303.00

Beyond Meat currently has a consensus price target of $121.1111, suggesting a potential downside of 8.76%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Beyond Meat.

Summary

Medifast beats Beyond Meat on 10 of the 13 factors compared between the two stocks.


Medifast Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Coca-Cola FEMSA logo
KOF
Coca-Cola FEMSA
1.6$48.87+1.7%$10.09 billion$10.11 billion23.61Upcoming Earnings
Dividend Increase
Decrease in Short Interest
News Coverage
Aramark logo
ARMK
Aramark
1.4$38.80+1.3%$9.73 billion$12.83 billion-21.20Analyst Upgrade
Increase in Short Interest
Albertsons Companies logo
ACI
Albertsons Companies
1.7$19.63+3.5%$9.45 billion$62.46 billion0.00Upcoming Earnings
Analyst Revision
News Coverage
Service Co. International logo
SCI
Service Co. International
1.9$51.84+0.2%$8.76 billion$3.23 billion20.33
US Foods logo
USFD
US Foods
1.7$38.74+1.7%$8.42 billion$25.94 billion-61.49Analyst Report
Beyond Meat logo
BYND
Beyond Meat
1.1$132.25+0.6%$8.28 billion$297.90 million-293.89
The New York Times logo
NYT
The New York Times
1.8$48.15+0.7%$8.12 billion$1.81 billion50.68
Freshpet logo
FRPT
Freshpet
1.7$175.13+3.0%$7.33 billion$245.86 million1,592.24
Post logo
POST
Post
1.5$113.13+1.0%$7.21 billion$5.70 billion-3,769.74Unusual Options Activity
Coty logo
COTY
Coty
1.2$9.11+4.6%$6.66 billion$4.72 billion-7.85Analyst Revision
Ingredion logo
INGR
Ingredion
2.2$92.80+0.6%$6.20 billion$6.21 billion18.34
Ollie's Bargain Outlet logo
OLLI
Ollie's Bargain Outlet
0.9$96.43+1.9%$6.20 billion$1.41 billion27.87
Pilgrim's Pride logo
PPC
Pilgrim's Pride
1.5$24.58+1.2%$5.92 billion$11.41 billion32.34Upcoming Earnings
Decrease in Short Interest
Helen of Troy logo
HELE
Helen of Troy
1.3$230.31+0.3%$5.64 billion$1.71 billion25.56Upcoming Earnings
Analyst Report
News Coverage
Flowers Foods logo
FLO
Flowers Foods
1.3$24.50+0.6%$5.16 billion$4.12 billion53.26
Nomad Foods logo
NOMD
Nomad Foods
1.5$29.32+0.4%$5.07 billion$2.60 billion24.43
National Beverage logo
FIZZ
National Beverage
1.3$54.32+0.9%$5.02 billion$1.00 billion15.79
Lancaster Colony logo
LANC
Lancaster Colony
2.0$185.15+1.8%$5.01 billion$1.33 billion38.25News Coverage
Leslie's logo
LESL
Leslie's
1.2$25.65+0.7%$4.76 billion$1.11 billion61.07Analyst Report
Unusual Options Activity
51job logo
JOBS
51job
1.3$62.50+0.6%$4.24 billion$574.57 million29.48News Coverage
The Hain Celestial Group logo
HAIN
The Hain Celestial Group
1.5$42.22+0.2%$4.21 billion$2.05 billion162.38Unusual Options Activity
News Coverage
Celsius logo
CELH
Celsius
1.5$57.90+4.3%$4.02 billion$75.15 million827.26
Grocery Outlet logo
GO
Grocery Outlet
1.2$39.05+1.7%$3.66 billion$2.56 billion41.11
Sanderson Farms logo
SAFM
Sanderson Farms
1.7$166.50+2.2%$3.63 billion$3.56 billion132.14Decrease in Short Interest
Hillenbrand logo
HI
Hillenbrand
2.0$48.97+2.6%$3.58 billion$2.52 billion-60.46News Coverage
BRF logo
BRFS
BRF
1.3$4.33+0.2%$3.51 billion$8.13 billion13.97News Coverage
Compañía Cervecerías Unidas logo
CCU
Compañía Cervecerías Unidas
1.5$19.01+1.1%$3.48 billion$2.41 billion27.96Dividend Announcement
Energizer logo
ENR
Energizer
2.4$50.97+1.2%$3.44 billion$2.74 billion-32.26Analyst Upgrade
News Coverage
WD-40 logo
WDFC
WD-40
1.6$259.38+3.4%$3.43 billion$423.35 million58.95
Utz Brands logo
UTZ
Utz Brands
1.5$26.23+6.1%$3.37 billionN/A0.00Analyst Downgrade
News Coverage
Gap Down
The Simply Good Foods logo
SMPL
The Simply Good Foods
1.6$33.53+1.6%$3.16 billion$816.64 million53.22
JW.B
John Wiley & Sons
0.6$56.13+0.0%$3.14 billion$1.83 billion-81.35
J & J Snack Foods logo
JJSF
J & J Snack Foods
1.6$161.91+1.1%$3.04 billion$1.02 billion170.43Upcoming Earnings
Coca-Cola Consolidated logo
COKE
Coca-Cola Consolidated
0.7$311.30+1.5%$2.88 billion$4.83 billion30.61
TreeHouse Foods logo
THS
TreeHouse Foods
1.2$51.06+0.4%$2.87 billion$4.29 billion-510.60
Nu Skin Enterprises logo
NUS
Nu Skin Enterprises
2.1$54.32+0.7%$2.78 billion$2.42 billion18.29News Coverage
Tootsie Roll Industries logo
TR
Tootsie Roll Industries
0.9$33.66+0.2%$2.29 billion$523.62 million38.53Upcoming Earnings
Industrias Bachoco logo
IBA
Industrias Bachoco
1.6$45.42+0.2%$2.27 billion$3.26 billion16.82Upcoming Earnings
Purple Innovation logo
PRPL
Purple Innovation
2.1$34.73+3.7%$2.23 billion$428.36 million-112.03Analyst Report
News Coverage
Inter Parfums logo
IPAR
Inter Parfums
1.6$75.25+7.0%$2.21 billion$713.51 million75.25Analyst Report
News Coverage
Gap Down
Edgewell Personal Care logo
EPC
Edgewell Personal Care
1.8$39.49+1.7%$2.11 billion$1.95 billion31.85
Vector Group logo
VGR
Vector Group
1.3$13.79+1.5%$2.09 billion$1.90 billion31.34
Hostess Brands logo
TWNK
Hostess Brands
1.1$15.24+1.0%$1.97 billion$907.67 million30.48
B&G Foods logo
BGS
B&G Foods
1.6$30.63+1.2%$1.96 billion$1.66 billion15.16
United Natural Foods logo
UNFI
United Natural Foods
1.4$34.52+3.0%$1.88 billion$26.51 billion18.17Insider Selling
e.l.f. Beauty logo
ELF
e.l.f. Beauty
1.3$29.71+0.5%$1.52 billion$282.85 million156.38Analyst Report
Schweitzer-Mauduit International logo
SWM
Schweitzer-Mauduit International
1.4$46.61+0.6%$1.46 billion$1.02 billion16.53
Franchise Group logo
FRG
Franchise Group
2.8$36.81+2.0%$1.45 billion$132.55 million0.00
SunOpta logo
STKL
SunOpta
1.7$13.98+1.4%$1.43 billion$1.19 billion-107.54Analyst Report
UVV
Universal
1.2$57.88+2.3%$1.43 billion$1.91 billion25.61
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.